Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Improving Surgery for Crohn's Disease

By HospiMedica staff writers
Posted on 12 Mar 2007
A new study released after decades of research examines the management of bowel stricture recurrence in patients who undergo surgery for Crohn's disease, and provides guidance to surgeons and gastroenterologists battling this intestinal disorder.

Researchers from the University of Chicago (IL, USA), led by Dr. More...
Fabrizio Michelassi--now professor of surgery at Weill Cornell Medical College (New York, NY, USA)--examined data collected by Dr. Michelassi during nearly 20 years (1984-2004) of his tenure at the University of Chicago. Dr. Michelassi was able to keep records on 981 patients who underwent a total of 1,132 procedures, 668 of which involved recurrent disease. During each procedure, he took pictures and made detailed sketches of those areas subject to surgery.

The study revealed several insights: First of all, it validated the notion that strictureplasty--a bowel-sparing surgical procedure commonly used to correct Crohn's-related strictures--carries a lower risk of stricture recurrence compared to resection, and that if a recurrence does occur after strictureplasty, it is likely to happen much later than after resection. The study found that recurrences after strictureplasty were also less likely to require a surgical excision of the affected area compared to recurrences occurring after resection. The study also found that up to a third of recurrences occur away from the site of the original operation. Among other findings, the study supports the notion that strictureplasty is less likely to lead to stricture recurrence later on, compared to surgical resection of the stricture.

"Based on our findings, we would now advise that if an asymptomatic stricture can be fixed using bowel-sparing strictureplasty, then the surgeon should go ahead and perform that type of prophylactic procedure,” said Dr. Michelassi. "However, if fixing the problem requires bowel resection, then we would advise leaving the stricture alone, because there's still a 75% chance it will not cause the patient any harm.”

Crohn's disease involves a chronic inflammation of the digestive tract, often resulting in pain and diarrhea. Disease onset typically occurs in young adulthood, and the disorder is characterized by strictures--narrowings of the bowel--that often require surgical excision or correction. There is currently no cure for Crohn's.


Related Links:
University of Chicago
Weill Cornell Medical College

Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Gas Consumption Analyzer
Anesthetic Gas Consumption Analyzer
Radiation Safety Barrier
RayShield Intensi-Barrier
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The researchers grew pancreatic tissue (above) so it incorporated a mesh-like electronic network (red). Cells within the tissue produce insulin (green). (Photo courtesy of Penn Medicine)

‘Cyborg’ Transplants Could Replace Pancreatic Tissue Damaged by Diabetes

Type 1 diabetes destroys insulin-producing islet cells, forcing patients to rely on lifelong insulin therapy or scarce organ transplants. Although lab-grown pancreatic tissue offers a promising alternative,... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.